▶ 調査レポート

呼吸器系抗ウイルス治療の世界市場2020-2030:医薬品クラス別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)、疾患種類別、流通チャネル別

• 英文タイトル:Respiratory Antiviral Treatment Market (Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, and Fusion Protein Inhibitors; Disease Type: Influenza, Bronchiolitis, Pneumonia, Upper Respiratory Tract Infections (URTIs), and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Transparency Market Researchが調査・発行した産業分析レポートです。呼吸器系抗ウイルス治療の世界市場2020-2030:医薬品クラス別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)、疾患種類別、流通チャネル別 / Respiratory Antiviral Treatment Market (Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, and Fusion Protein Inhibitors; Disease Type: Influenza, Bronchiolitis, Pneumonia, Upper Respiratory Tract Infections (URTIs), and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030 / D0SP201105資料のイメージです。• レポートコード:D0SP201105
• 出版社/出版日:Transparency Market Research / 2020年10月30日
• レポート形態:英文、PDF、204ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥764,940 (USD5,795)▷ お問い合わせ
  Multi User¥1,160,940 (USD8,795)▷ お問い合わせ
  Corporate License¥1,556,940 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本市場調査レポートでは、呼吸器系抗ウイルス治療の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場動向、医薬品クラス別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)分析、疾患種類別(インフルエンザ、細気管支炎、肺炎、上気道感染症(URTI)、その他)分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局)分析、最終用途別(商業用、非商業用)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などの項目を掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場概要
・市場動向
・呼吸器系抗ウイルス治療の世界市場規模:医薬品クラス別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)
・呼吸器系抗ウイルス治療の世界市場規模:疾患種類別(インフルエンザ、細気管支炎、肺炎、上気道感染症(URTI)、その他)
・呼吸器系抗ウイルス治療の世界市場規模:流通チャネル別(病院薬局、小売薬局、オンライン薬局)
・呼吸器系抗ウイルス治療の世界市場規模:最終用途別(商業用、非商業用)
・呼吸器系抗ウイルス治療の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Respiratory Antiviral Treatment Market – Scope of the Report

TMR’s report on the global respiratory antiviral treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory antiviral treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global respiratory antiviral treatment market from 2020 to 2030.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory antiviral treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the respiratory antiviral treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global respiratory antiviral treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory antiviral treatment market.

The report delves into the competition landscape of the global respiratory antiviral treatment market. Key players operating in the global respiratory antiviral treatment market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory antiviral treatment market profiled in this report.

Key Questions Answered in Respiratory Antiviral Treatment Market Report

What is the sales/revenue generated by respiratory antiviral treatment across all regions during the forecast period?
What are the opportunities in the global respiratory antiviral treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Respiratory Antiviral Treatment Market – Research Objectives and Research Approach

The comprehensive report on the global respiratory antiviral treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory antiviral treatment market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory antiviral treatment market.

レポート目次

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Key Industry Developments

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity

4.4. Global Respiratory Antiviral Treatment Market Forecast

4.5. Global Respiratory Antiviral Treatment Market Outlook

5. Market Outlook

5.1. Pipeline Analysis

5.2. Disease Prevalence Rate Globally with Key Countries

5.3. COVID-19 Impact Analysis

6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

6.1. Introduction

6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class

6.3.1. Nucleoside Analogs

6.3.1.1. Ribavirin

6.3.1.2. Aciclovir

6.3.1.3. Others

6.3.2. Neuraminidase Inhibitors

6.3.2.1. Oseltamivir

6.3.2.2. Zanamivir

6.3.2.3. Others

6.3.3. Ion Channel Blockers

6.3.4. Fusion Protein Inhibitors

6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

7.1. Introduction

7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type

7.3.1. Influenza

7.3.2. Bronchiolitis

7.3.3. Pneumonia

7.3.4. Upper Respiratory Tract Infections (URTIs)

7.3.5. Others (measles, etc.)

7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel

8.1. Introduction

8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration

9. Global Respiratory Antiviral Treatment Market Analysis, by Region

9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country

9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region

9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region

9.3.1. North America

9.3.2. Europe

9.3.3. Asia Pacific

9.3.4. Latin America

9.3.5. Middle East & Africa

10. North America Respiratory Antiviral Treatment Market Analysis

10.1. North America Respiratory Antiviral Treatment Market Overview

10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country

10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country

10.3.1. U.S.

10.3.2. Canada

10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class

10.5.1. Nucleoside Analogs

10.5.1.1. Ribavirin

10.5.1.2. Aciclovir

10.5.1.3. Others

10.5.2. Neuraminidase Inhibitors

10.5.2.1. Oseltamivir

10.5.2.2. Zanamivir

10.5.2.3. Others

10.5.3. Ion Channel Blockers

10.5.4. Fusion Protein Inhibitors

10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type

10.7.1. Influenza

10.7.2. Bronchiolitis

10.7.3. Pneumonia

10.7.4. Upper Respiratory Tract Infections (URTIs)

10.7.5. Others (measles, etc.)

10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

10.9.1. Hospital Pharmacies

10.9.2. Retail Pharmacies

10.9.3. Online Pharmacies

11. Europe Respiratory Antiviral Treatment Market Analysis

11.1. Europe Respiratory Antiviral Treatment Market Overview

11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

11.3.1. Germany

11.3.2. France

11.3.3. U.K.

11.3.4. Italy

11.3.5. Spain

11.3.6. Rest of Europe

11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class

11.5.1. Nucleoside Analogs

11.5.1.1. Ribavirin

11.5.1.2. Aciclovir

11.5.1.3. Others

11.5.2. Neuraminidase Inhibitors

11.5.2.1. Oseltamivir

11.5.2.2. Zanamivir

11.5.2.3. Others

11.5.3. Ion Channel Blockers

11.5.4. Fusion Protein Inhibitors

11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type

11.7.1. Influenza

11.7.2. Bronchiolitis

11.7.3. Pneumonia

11.7.4. Upper Respiratory Tract Infections (URTIs)

11.7.5. Others (measles, etc.)

11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

11.9.1. Hospital Pharmacies

11.9.2. Retail Pharmacies

11.9.3. Online Pharmacies

12. Asia Pacific Respiratory Antiviral Treatment Market Analysis

12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview

12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

12.3.1. Japan

12.3.2. China

12.3.3. India

12.3.4. Australia & New Zealand

12.3.5. Rest of Asia Pacific

12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class

12.5.1. Nucleoside Analogs

12.5.1.1. Ribavirin

12.5.1.2. Aciclovir

12.5.1.3. Others

12.5.2. Neuraminidase Inhibitors

12.5.2.1. Oseltamivir

12.5.2.2. Zanamivir

12.5.2.3. Others

12.5.3. Ion Channel Blockers

12.5.4. Fusion Protein Inhibitors

12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type

12.7.1. Influenza

12.7.2. Bronchiolitis

12.7.3. Pneumonia

12.7.4. Upper Respiratory Tract Infections (URTIs)

12.7.5. Others (measles, etc.)

12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

12.9.1. Hospital Pharmacies

12.9.2. Retail Pharmacies

12.9.3. Online Pharmacies

13. Latin America Respiratory Antiviral Treatment Market Analysis

13.1. Latin America Respiratory Antiviral Treatment Market Overview

13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

13.3.1. Brazil

13.3.2. Mexico

13.3.3. Rest of Latin America

13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class

13.5.1. Nucleoside Analogs

13.5.1.1. Ribavirin

13.5.1.2. Aciclovir

13.5.1.3. Others

13.5.2. Neuraminidase Inhibitors

13.5.2.1. Oseltamivir

13.5.2.2. Zanamivir

13.5.2.3. Others

13.5.3. Ion Channel Blockers

13.5.4. Fusion Protein Inhibitors

13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type

13.7.1. Influenza

13.7.2. Bronchiolitis

13.7.3. Pneumonia

13.7.4. Upper Respiratory Tract Infections (URTIs)

13.7.5. Others (measles, etc.)

13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

13.9.1. Hospital Pharmacies

13.9.2. Retail Pharmacies

13.9.3. Online Pharmacies

14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis

14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview

14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

14.3.1. GCC Countries

14.3.2. South Africa

14.3.3. Rest of Middle East & Africa

14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class

14.5.1. Nucleoside Analogs

14.5.1.1. Ribavirin

14.5.1.2. Aciclovir

14.5.1.3. Others

14.5.2. Neuraminidase Inhibitors

14.5.2.1. Oseltamivir

14.5.2.2. Zanamivir

14.5.2.3. Others

14.5.3. Ion Channel Blockers

14.5.4. Fusion Protein Inhibitors

14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type

14.7.1. Influenza

14.7.2. Bronchiolitis

14.7.3. Pneumonia

14.7.4. Upper Respiratory Tract Infections (URTIs)

14.7.5. Others (measles, etc.)

14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

14.9.1. Hospital Pharmacies

14.9.2. Retail Pharmacies

14.9.3. Online Pharmacies

15. Competition Landscape

15.1. Competition Matrix

15.2. Company Profiles

15.2.1. F. Hoffmann-La Roche Ltd.

15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.1.2. Financial Overview

15.2.1.3. Product Portfolio

15.2.1.4. SWOT Analysis

15.2.1.5. Strategic Overview

15.2.2. Novartis AG

15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.2.2. Financial Overview

15.2.2.3. Product Portfolio

15.2.2.4. SWOT Analysis

15.2.2.5. Strategic Overview

15.2.3. Takeda Pharmaceutical Company Limited

15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.3.2. Financial Overview

15.2.3.3. Product Portfolio

15.2.3.4. SWOT Analysis

15.2.3.5. Strategic Overview

15.2.4. Pfizer, Inc.

15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.4.2. Product Portfolio

15.2.4.3. SWOT Analysis

15.2.4.4. Strategic Overview

15.2.5. Teva Pharmaceutical Industries Ltd.

15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.5.2. Financial Overview

15.2.5.3. Product Portfolio

15.2.5.4. SWOT Analysis

15.2.5.5. Strategic Overview

15.2.6. Sun Pharmaceutical Industries Ltd.

15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.6.2. Financial Overview

15.2.6.3. Product Portfolio

15.2.6.4. SWOT Analysis

15.2.6.5. Strategic Overview

15.2.7. GlaxoSmithKline plc

15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.7.2. Financial Overview

15.2.7.3. Product Portfolio

15.2.7.4. SWOT Analysis

15.2.7.5. Strategic Overview

15.2.8. Mylan, Inc.

15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.8.2. Financial Overview

15.2.8.3. Product Portfolio

15.2.8.4. SWOT Analysis

15.2.8.5. Strategic Overview

15.2.9. Merck & Co., Inc.

15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.9.2. Financial Overview

15.2.9.3. Product Portfolio

15.2.9.4. SWOT Analysis

15.2.9.5. Strategic Overview

15.2.10. AstraZeneca plc.

15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.10.2. Financial Overview

15.2.10.3. Product Portfolio

15.2.10.4. SWOT Analysis

15.2.10.5. Strategic Overview

List of Tables

Table 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030